Related Experiment Video
Updated: Mar 14, 2026
Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
Published on: May 23, 2025
Leptomeningeal metastases of solid cancer
Emilie Le Rhun1, Evanthia Galanis
1aBreast Unit, Department of Medical Oncology, Oscar Lambret Center bNeuro-oncology, Department of Neurosurgery, University Hospital cLille University, Inserm U-1192, Laboratoire de Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM), Lille, France dDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Purpose Of Review:
To review recent original data on leptomeningeal metastases in patients with solid cancer.
Recent Findings:
Lung and breast cancer as well as melanoma remain the most common primaries. Advanced cytological methods and targeted sequencing for candidate tumor-specific mutations may improve the sensitivity of cerebrospinal fluid diagnostics in leptomeningeal metastases. Targeted treatments like epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer, anti-human epidermal growth factor receptor-2 treatments for breast cancer or B-rapidly accelerated fibrosarcoma-targeted or immunotherapy for melanoma have an emerging role in the management of this condition.
Summary:
Novel diagnostic approaches and the introduction of targeted agents may improve the clinical management of patients with leptomeningeal metastases from solid cancers.
